Ochratoxin A activates opposing c-MET/PI3K/Akt and MAPK/ERK 1-2 pathways in human proximal tubule HK-2 cells

Archives of Toxicology

Volumn 89, Issue 8, 2015, Pages 1313-1327

  Özcan, Zeynep ^a,b   Gül, Gizem ^a   Yaman, Ibrahim ^a  

^a BOGAZICI UNIVERSITY   (Turkey)

^b GEBZE TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Akt; Apoptosis; c MET; ERK1 2; HK 2 cells; Ochratoxin A

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; OCHRATOXIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; WORTMANNIN; POLLUTANT;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; KIDNEY PROXIMAL TUBULE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; CELL CULTURE TECHNIQUE; CELL LINE; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOLOGY; POLLUTANT; TIME FACTOR; TOXICITY;

APOPTOSIS; CELL CULTURE TECHNIQUES; CELL LINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL POLLUTANTS; EPITHELIAL CELLS; HUMANS; KIDNEY TUBULES, PROXIMAL; MAP KINASE SIGNALING SYSTEM; OCHRATOXINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-MET; TIME FACTORS;

EID: 84937966766     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-014-1311-x     Document Type: Article

References (86)

1. Alessi DR, James SR, Downes CP et al (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Curr Biol 7(4):261–269
2. Alvarez L, Gil AG, Ezpeleta O, Garcia-Jalon JA, Lopez de Cerain A (2004) Immunotoxic effects of Ochratoxin A in Wistar rats after oral administration. Food Chem Toxicol 42(5):825–834
3. Arbillaga L, Azqueta A, Ezpeleta O, Lopez de Cerain A (2007a) Oxidative DNA damage induced by Ochratoxin A in the HK-2 human kidney cell line: evidence of the relationship with cytotoxicity. Mutagenesis 22(1):35–42
4. Arbillaga L, Azqueta A, van Delft JH, Lopez de Cerain A (2007b) In vitro gene expression data supporting a DNA non-reactive genotoxic mechanism for ochratoxin A. Toxicol Appl Pharmacol 220(2):216–224
5. Banumathy G, Cairns P (2010) Signaling pathways in renal cell carcinoma. Cancer Biol Ther 10(7):658–664
6. Boorman GA, McDonald MR, Imoto S, Persing R (1992) Renal lesions induced by Ochratoxin A Exposure in the F344 Rat. Toxicol Pathol 20(2):236–245
7. Chambard JC, Lefloch R, Pouyssegur J, Lenormand P (2007) ERK implication in cell cycle regulation. Biochim Biophys Acta 1773(8):1299–1310
8. Christensen JG, Schreck R, Burrows J et al (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63(21):7345–7355
9. Clark HA, Snedeker SM (2006) Ochratoxin a: its cancer risk and potential for exposure. J Toxicol Environ Health B Crit Rev 9(3):265–296
10. Cohen GM (1997) Caspases: the executioners of apoptosis. Biochem J 326:1–16
11. Cui J, Liu J, Wu S et al (2013) Oxidative DNA damage is involved in ochratoxin A-induced G2 arrest through ataxia telangiectasia-mutated (ATM) pathways in human gastric epithelium GES-1 cells in vitro. Arch Toxicol 87(10):1829–1840
12. Dai J, Park G, Perry JL et al (2004) Molecular aspects of the transport and toxicity of ochratoxin a. Acc Chem Res 37(11):874–881
13. Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26(22):3279–3290
14. Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM (2011) HGF-independent potentiation of EGFR action by c-Met. Oncogene 30(33):3625–3635
15. Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039–1043
16. FAO/WHO (2001) Safety evaluation of certain mycotoxins in food. World Health Organization: IPCS, Geneva
17. Faucet V, Pfohl-Leszkowicz A, Dai J, Castegnaro M, Manderville RA (2004) Evidence for covalent DNA adduction by ochratoxin A following chronic exposure to rat and subacute exposure to pig. Chem Res Toxicol 17(9):1289–1296
18. Franke TF, Yang SI, Chan TO et al (1995) The protein-kinase encoded by the Akt protooncogene is a target of the Pdgf-activated phosphatidylinositol 3-Kinase. Cell 81(5):727–736
19. Gautier J, Richoz J, Welti DH et al (2001) Metabolism of ochratoxin A: absence of formation of genotoxic derivatives by human and rat enzymes. Chem Res Toxicol 14(1):34–45
20. Gekle M, Schwerdt G, Freudinger R et al (2000) Ochratoxin A induces JNK activation and apoptosis in MDCK-C7 cells at nanomolar concentrations. J Pharmacol Exp Ther 293(3):837–844
21. Gekle M, Sauvant C, Schwerdt G (2005) Ochratoxin A at nanomolar concentrations: a signal modulator in renal cells. Mol Nutr Food Res 49(2):118–130
22. Gross-Steinmeyer K, Weymann J, Hege HG, Metzler M (2002) Metabolism and lack of DNA reactivity of the mycotoxin ochratoxin A in cultured rat and human primary hepatocytes. J Agr Food Chem 50(4):938–945
23. Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M (2005) Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 16(6):928–933
24. Hoffmann D, Fuchs TC, Henzler T et al (2010) Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity. Toxicology 277(1–3):49–58
25. Hong SK, Yoon S, Moelling C, Arthan D, Park JI (2009) Noncatalytic function of ERK1/2 can promote Raf/MEK/ERK-mediated growth arrest signaling. J Biol Chem 284(48):33006–33018
26. Horvath A, Upham BL, Ganev V, Trosko JE (2002) Determination of the epigenetic effects of ochratoxin in a human kidney and a rat liver epithelial cell line. Toxicon 40(3):273–282
27. Hult K, Plestina R, Habazin-Novak V, Radic B, Ceovic S (1982) Ochratoxin-a in human-blood and Balkan endemic nephropathy. Arch Toxicol 51(4):313–321
28. Jeffers M, Schmidt L, Nakaigawa N et al (1997) Activating mutations for the Met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA 94(21):11445–11450
29. Jennings P, Weiland C, Limonciel A et al (2012) Transcriptomic alterations induced by Ochratoxin A in rat and human renal proximal tubular in vitro models and comparison to a rat in vivo model. Arch Toxicol 86(4):571–589
30. Jennings-Gee JE, Tozlovanu M, Manderville R, Miller MS, Pfohl-Leszkowicz A, Schwartz GG (2010) Ochratoxin A: in utero exposure in mice induces adducts in testicular DNA. Toxins 2(6):1428–1444
31. Jo SK, Cho WY, Sung SA, Kim HK, Won NH (2005) MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int 67(2):458–466
32. Kuiper-Goodman T (1996) Risk assessment of ochratoxin A: an update. Food Addit Contam 13:53–57
33. Kumar M, Dwivedi P, Sharma AK, Singh ND, Patil RD (2007) Ochratoxin A and citrinin nephrotoxicity in New Zealand White rabbits: an ultrastructural assessment. Mycopathologia 163(1):21–30
34. Kumar R, Ansari KM, Chaudhari BP et al (2012) Topical application of ochratoxin A causes DNA damage and tumor initiation in mouse skin. PLoS ONE 7(10):e47280
35. Kumar R, Alam S, Chaudhari BP et al (2013) Ochratoxin A-induced cell proliferation and tumor promotion in mouse skin by activating the expression of cyclin-D1 and cyclooxygenase-2 through nuclear factor-kappa B and activator protein-1. Carcinogenesis 34(3):647–657
36. Lakhani SA, Masud A, Kuida K et al (2006) Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 311(5762):847–851
37. Lee S, Choi EJ, Jin C, Kim DH (2005) Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97(1):26–34
38. Li J, Yin S, Dong Y, Fan L, Hu H (2011) p53 activation inhibits ochratoxin A-induced apoptosis in monkey and human kidney epithelial cells via suppression of JNK activation. Biochem Biophys Res Commun 411(2):458–463
39. Linehan WM, Srinivasan R, Schmidt LS (2010) The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 7(5):277–285
40. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8):627–644
41. Ma FY, Liu J, Nikolic-Paterson DJ (2009) The role of stress-activated protein kinase signaling in renal pathophysiology. Braz J Med Biol Res 42(1):29–37
42. Mally A (2012) Ochratoxin A and mitotic disruption: mode of action analysis of renal tumor formation by ochratoxin A. Toxicol Sci 127(2):315–330
43. Mally A, Zepnik H, Wanek P et al (2004) Ochratoxin A: lack of formation of covalent DNA adducts. Chem Res Toxicol 17(2):234–242
44. Mantle P, Kulinskaya E, Nestler S (2005) Renal tumourigenesis in male rats in response to chronic dietary ochratoxin A. Food Addit Contam A 22:58–64
45. Marin-Kuan M, Nestler S, Verguet C et al (2007) MAPK-ERK activation in kidney of male rats chronically fed ochratoxin A at a dose causing a significant incidence of renal carcinoma. Toxicol Appl Pharmacol 224(2):174–181
46. Marin-Kuan M, Ehrlich V, Delatour T, Cavin C, Schilter B (2011) Evidence for a role of oxidative stress in the carcinogenicity of ochratoxin a. J Toxicol 2011:645361
47. McCubrey JA, Steelman LS, Abrams SL et al (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249–279
48. Mosesso P, Cinelli S, Pinero J, Bellacima R, Pepe G (2008) In vitro cytogenetic results supporting a DNA nonreactive mechanism for Ochratoxin A, potentially relevant for its carcinogenicity. Chem Res Toxicol 21(6):1235–1243
49. Nowak G (2002) Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+transport, and cisplatin-induced apoptosis in renal cells. J Biol Chem 277(45):43377–43388
50. Obrecht-Pflumio S, Dirheimer G (2000) In vitro DNA and dGMP adducts formation caused by ochratoxin A. Chem-Biol Interact 127(1):29–44
51. O’Brien E, Dietrich DR (2005) Ochratoxin A: the continuing enigma. Crit Rev Toxicol 35(1):33–60
52. Park HS, Kim MS, Huh SH et al (2002) Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation. J Biol Chem 277(4):2573–2578
53. Petrik J, Zanic-Grubisic T, Barisic K et al (2003) Apoptosis and oxidative stress induced by ochratoxin A in rat kidney. Arch Toxicol 77(12):685–693
54. Pfohl-Leszkowicz A (2009) Ochratoxin A and aristolochic acid involvement in nephropathies and associated urothelial tract tumours. Arh Hig Rada Toksikol 60(4):465–483
55. Pfohl-Leszkowicz A, Manderville RA (2007) Ochratoxin A: an overview on toxicity and carcinogenicity in animals and humans. Mol Nutr Food Res 51(1):61–99
56. Pfohl-Leszkowicz A, Petkova-Bocharova T, Chernozemsky IN, Castegnaro M (2002) Balkan endemic nephropathy and associated urinary tract tumours: a review on aetiological causes and the potential role of mycotoxins. Food Addit Contam 19(3):282–302
57. Qian CN, Furge KA, Knol J et al (2009) Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. Cancer Res 69(21):8256–8264
58. Rached E, Pfeiffer E, Dekant W, Mally A (2006) Ochratoxin A: apoptosis and aberrant exit from mitosis due to perturbation of microtubule dynamics? Toxicol Sci 92(1):78–86
59. Rached E, Hard GC, Blumbach K et al (2007) Ochratoxin A: 13-week oral toxicity and cell proliferation in male F344/n rats. Toxicol Sci 97(2):288–298
60. Samuels Y, Diaz LA Jr, Schmidt-Kittler O et al (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6):561–573
61. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712):1098–1101
62. Sauvant C, Holzinger H, Gekle M (2005) Proximal tubular toxicity of ochratoxin A is amplified by simultaneous inhibition of the extracellular signal-regulated kinases 1/2. J Pharmacol Exp Ther 313(1):234–241
63. Sava V, Reunova O, Velasquez A, Harbison R, Sanchez-Ramos J (2006) Acute neurotoxic effects of the fungal metabolite ochratoxin-A. Neurotoxicology 27(1):82–92
64. Schilter B, Marin-Kuan M, Delatour T, Nestler S, Mantle P, Cavin C (2005) Ochratoxin A: potential epigenetic mechanisms of toxicity and carcinogenicity. Food Addit Contam 22:88–93
65. Schramek H, Wilflingseder D, Pollack V, Freudinger R, Mildenberger S, Gekle M (1997) Ochratoxin A-induced stimulation of extracellular signal-regulated kinases 1/2 is associated with Madin-Darby canine kidney-C7 cell dedifferentiation. J Pharmacol Exp Ther 283(3):1460–1468
66. Sonnenberg E, Meyer D, Weidner KM, Birchmeier C (1993) Scatter factor hepatocyte growth-factor and its receptor, the C-Met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 123(1):223–235
67. Steelman LS, Chappell WH, Abrams SL et al (2011) Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 3(3):192–222
68. Stemmer K, Ellinger-Ziegelbauer H, Ahr HJ, Dietrich DR (2007) Carcinogen-specific gene expression profiles in short-term treated Eker and wild-type rats indicative of pathways involved in renal tumorigenesis. Cancer Res 67(9):4052–4068
69. Subramaniam S, Zirrgiebel U, von Bohlen Und Halbach O et al (2004) ERK activation promotes neuronal degeneration predominantly through plasma membrane damage and independently of caspase-3. J Cell Biol 165(3):357–369
70. Suzuki Y, Murakami H, Kawaguchi K et al (2009) Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep 2(2):181–188
71. Tang D, Okada H, Ruland J et al (2001) Akt is activated in response to an apoptotic signal. J Biol Chem 276(32):30461–30466
72. Tewari M, Quan LT, Orourke K et al (1995) Yama/CPP32-Beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81(5):801–809
73. Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD (2008) Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis 25(8):843–854
74. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR (2000) Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 20(14):5010–5018
75. Wang X, Martindale JL, Holbrook NJ (2000) Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275(50):39435–39443
76. Wang Y, Liu J, Cui J et al (2012) ERK and p38 MAPK signaling pathways are involved in ochratoxin A-induced G2 phase arrest in human gastric epithelium cells. Toxicol Lett 209(2):186–192
77. WHO/IARC (1993) Some naturally occurring substances: food items and constituents, heterocyclic aromatic amines and mycotoxins. IARC Monogr Eval Carcinog Risk Chem Hum 56:489
78. Woods DC, Johnson AL (2006) Phosphatase activation by epidermal growth factor family ligands regulates extracellular regulated kinase signaling in undifferentiated hen granulosa cells. Endocrinology 147(10):4931–4940
79. Wymann MP, Zvelebil M, Laffargue M (2003) Phosphoinositide 3-kinase signalling: which way to target? Trends Pharmacol Sci 24(7):366–376
80. Xu AM, Huang PH (2010) Receptor tyrosine kinase coactivation networks in cancer. Cancer Res 70(10):3857–3860
81. Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM (2011) Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res 17(13):4425–4438
82. Yoon S, Cong WT, Bang Y et al (2009) Proteome response to ochratoxin A-induced apoptotic cell death in mouse hippocampal HT22 cells. Neurotoxicology 30(4):666–676
83. Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41):5497–5510
84. Zhang Q, Claret FX (2012) Phosphatases: the new brakes for cancer development? Enzyme Res 2012:659649
85. Zhuang S, Schnellmann RG (2006) A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther 319(3):991–997
86. Zlender V, Breljak D, Ljubojevic M et al (2009) Low doses of ochratoxin A upregulate the protein expression of organic anion transporters Oat1, Oat2, Oat3 and Oat5 in rat kidney cortex. Toxicol Appl Pharmacol 239(3):284–296